DK200001897A - Fremgangsmåde til aktivering af genteknologisk fremstillede, heterologe, disulfidbroer indeholdende eukaryotiske proteiner - Google Patents

Fremgangsmåde til aktivering af genteknologisk fremstillede, heterologe, disulfidbroer indeholdende eukaryotiske proteiner Download PDF

Info

Publication number
DK200001897A
DK200001897A DK200001897A DKPA200001897A DK200001897A DK 200001897 A DK200001897 A DK 200001897A DK 200001897 A DK200001897 A DK 200001897A DK PA200001897 A DKPA200001897 A DK PA200001897A DK 200001897 A DK200001897 A DK 200001897A
Authority
DK
Denmark
Prior art keywords
pref
denaturing
esp
disulfide bridges
eukaryotic proteins
Prior art date
Application number
DK200001897A
Other languages
English (en)
Inventor
Stephan Fischer
Ralf Mattes
Rudolph Rainer
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of DK200001897A publication Critical patent/DK200001897A/da
Application granted granted Critical
Publication of DK175109B1 publication Critical patent/DK175109B1/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6456Plasminogen activators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6456Plasminogen activators
    • C12N9/6459Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/565IFN-beta
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21069Protein C activated (3.4.21.69)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Description

PATENTKRAV 1. Fremgangsmåde til aktivering af heterologe, disulfidbro-holdige eukaryotiske proteiner, fremstillet genteknologisk ved ekspression i prokaryotiske celler ved a) oplukning af de prokaryotiske celler, b) opløsning af de eukaryotiske proteiner under denaturerende og reducerende betingelser, c) fraskillelse af de reducerende/denaturerende midler, d) reaktivering under oxiderende betingelser ved e) omdannelse af de solubiliserede proteiners thiol-grupper til de blandede disulfider af protein og glutation ved tilsætning af GSSG under denaturerende betingelser, f) dannelse af aktivt protein ud fra de blandede disulfider ved en GSH-koncentration på 0,5 til 5 mmol/1, en pH-værdi på 7 til 10,5 og i nærværelse af en ikke-dena-turerende koncentration af et denatueringsmiddel. 2. Fremgangsmåde ifølge krav 1, kendetegnet ved, at man gennemfører ekspressionen i E. coli eller P. putida. 3. Fremgangmåde ifølge krav 1 eller 2, kendetegnet ved, at man i reaktiveringstrinnet som denatureringsmiddel anvender arginin, guanidin-hydrochlorid og/eller mindst en forbindelse med den almene formel R2-CO-NRRi (I), hvor R og R, er H eller alkyl med 1 til 4 C-atomer, og R2 er H eller NHR, eller alkyl med 1 til 3 C-atomer. 4. Fremgangsmåde ifølge krav 3, kendetegnet ved, at koncentrationen af arginin og/eller guanidin-hydrochlorid andrager 0,1 til 1,0 mol/1, navnlig 0,25 til 0,8 mol/1. 5. Fremgangsmåde ifølge krav 3, kendetegnet ved, at koncentrationen af forbindelsen med den almene formel I andrager 0,5 til 4 mol/1, navnlig 1 til 3,5 mol/1. 6. Fremgangsmåde ifølge ethvert af de foregående krav, kendetegnet ved, at der ved reaktiveringstrinnet arbejdes ved tilstedeværelse af et ikke-proteolytisk virksomt protein, navnlig ved tilstedeværelse af okseserumalbumin. 7. Fremgangsmåde ifølge ethvert af de foregående krav, kendetegnet ved, at man gennemfører celleoplukningen ved hjælp af ultralyd, højttryksdispersion eller Iysozym. 8. Fremgangsmåde ifølge krav 7, kendetegnet ved, at man gennemfører oplukningen i en fortyndet vandig pufferopløsning, navnlig i 0,1 mol/1 Tris, ved en neutral til svagt sur pH-værdi. 9. Fremgangsmåde ifølge ethvert af de foregående krav, kendetegnet ved, at man efter celleoplukningen fraskiller de uopløselige bestanddele. 10. Fremgangsmåde ifølge ethvert af de foregående krav, kendetegnet ved, at man gennemfører solubiliseringstrinnet ved alkalisk pH-værdi i nærværelse af et reduktionsmiddel fra mercaptogruppen og i nærværelse af et denatureringsmiddel. 11. Fremgangsmåde ifølge krav 10, kendetegnet ved, at man arbejder i nærværelse af guanidin-hydrochlorid og/eller forbindelser med den almene formel I som denatureringsmiddel. 12. Fremgangsmåde ifølge krav 11, kendetegnet ved, at koncentrationen af guanidindhydrochlorid andrager 6 mol/1, koncentration af forbindelser med den almene formel I andrager 8 mol/I. 13. Fremgangsmåde ifølge ethvert af kravene 10 til 12, kendetegnet ved, at man arbejder ved tilstedeværelse af DTE, β-mercaptoethanol, cystein eller GSH. 14. Fremgangsmåde ifølge ethvert af de foregående krav, kendetegnet ved, at man gennemfører rensning og fraskillelse af reduktions-, oxidations- eller denaturerings-midler ved hjælp af sterisk udelukkelseschromatografi eller dialyse. 15. Fremgangsmåde ifølge ethvert af de foregående krav, kendetegnet ved, at man efter reaktiveringstrinnet gennemfører et rensningstrin ved hjælp af dialyse. 16. Fremgangsmåde ifølge ethvert af kravene 1 til 15, k e n d e t e g n e t ved, at man som genteknologisk fremstillet eukaryotisk protein anvender t-PA. 17. Stimulerbar, ikke-glycosyleret tPA, opnået i overensstemmelse med fremgangsmåden ifølge ethvert af kravene 1 til 16. 18. Fremgangsmåde ifølge krav 6, kendetegnet ved, at man ved hjælp af ionbyt-terbehandling fraskiller det blandede disulfid af protein og glutathion fra ik-ke-modificeret protein.
DK200001897A 1985-10-23 2000-12-18 Fremgangsmåde til aktivering af genteknologisk fremstillede, heterologe, disulfidbroer indeholdende eukaryotiske proteiner efter ekspression i prokaryotiske celler DK175109B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3537708 1985-10-23
DE19853537708 DE3537708A1 (de) 1985-10-23 1985-10-23 Verfahren zur aktivierung von t-pa nach expression in prokaryonten
DK198703203A DK175091B1 (da) 1985-10-23 1987-06-23 Fremgangsmåde til aktivering af genteknologisk fremstillede, heterologe, disulfidbro-holdige eukaryotiske proteiner efter ekspression i prokaryotiske celler
DK320387 1987-06-23

Publications (2)

Publication Number Publication Date
DK200001897A true DK200001897A (da) 2000-12-18
DK175109B1 DK175109B1 (da) 2004-06-07

Family

ID=6284269

Family Applications (2)

Application Number Title Priority Date Filing Date
DK198703203A DK175091B1 (da) 1985-10-23 1987-06-23 Fremgangsmåde til aktivering af genteknologisk fremstillede, heterologe, disulfidbro-holdige eukaryotiske proteiner efter ekspression i prokaryotiske celler
DK200001897A DK175109B1 (da) 1985-10-23 2000-12-18 Fremgangsmåde til aktivering af genteknologisk fremstillede, heterologe, disulfidbroer indeholdende eukaryotiske proteiner efter ekspression i prokaryotiske celler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK198703203A DK175091B1 (da) 1985-10-23 1987-06-23 Fremgangsmåde til aktivering af genteknologisk fremstillede, heterologe, disulfidbro-holdige eukaryotiske proteiner efter ekspression i prokaryotiske celler

Country Status (26)

Country Link
EP (3) EP0219874B1 (da)
JP (2) JPH0728745B2 (da)
KR (1) KR900009139B1 (da)
AT (2) ATE131489T1 (da)
AU (2) AU590029B2 (da)
CA (1) CA1329157C (da)
CZ (1) CZ280727B6 (da)
DD (1) DD260517A5 (da)
DE (3) DE3537708A1 (da)
DK (2) DK175091B1 (da)
ES (2) ES2020498T3 (da)
FI (2) FI94050C (da)
GR (2) GR920300062T1 (da)
HK (2) HK153496A (da)
HR (1) HRP921075B1 (da)
HU (2) HUT43643A (da)
IE (1) IE62634B1 (da)
IL (1) IL80325A (da)
PT (1) PT83609B (da)
SI (1) SI8611796B (da)
SK (1) SK278317B6 (da)
SU (1) SU1607689A3 (da)
UA (1) UA6023A1 (da)
WO (1) WO1987002673A2 (da)
YU (1) YU47185B (da)
ZA (1) ZA868012B (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
JP2581668B2 (ja) * 1985-11-27 1997-02-12 三井東圧化学株式会社 ヒト正常細胞由来のヒト組織プラスミノ−ゲン活性化因子をコ−ドする新しいdna配列とそれを含むベクタ−及び細胞
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
AU621051B2 (en) 1987-04-28 1992-03-05 Amgen, Inc. Method for purifying granulocyte-macrophage colony stimulating factor
DE3722082A1 (de) * 1987-07-03 1989-01-12 Behringwerke Ag Verfahren zur bestimmung der aktivitaet von serinproteasen oder serinproteaseinhibitoren
CA1340586C (en) * 1988-09-23 1999-06-08 Cetus Corporation Process for recovering microbially produced interferon-beta
DE3832898A1 (de) * 1988-09-28 1990-04-12 Boehringer Mannheim Gmbh Praeparat von in prokaryonten exprimiertem plasminogenaktivator
DE3835350A1 (de) * 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
ATE154073T1 (de) * 1990-08-20 1997-06-15 Novo Nordisk As Prozess für die herstellung von biologisch aktivem igf-1 durch verwendung von amino-terminal verlängertem igf-1
DE69129747T2 (de) * 1990-09-05 1998-11-12 Southern Cross Biotech Pty Ltd In lösung bringen von proteinen in aktiver form
DE4037196A1 (de) * 1990-11-22 1992-05-27 Boehringer Mannheim Gmbh Verfahren zur reaktivierung von denaturiertem protein
DE4113750A1 (de) 1991-04-26 1992-10-29 Boehringer Mannheim Gmbh Verbesserung der renaturierung bei der sekretion von disulfidverbrueckten proteinen
DE4139000A1 (de) 1991-11-27 1993-06-03 Boehringer Mannheim Gmbh Verfahren zur gentechnologischen herstellung von biologisch aktivem ss-ngf
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
WO1993019084A1 (en) * 1992-03-24 1993-09-30 Synergen, Inc. Refolding and purification of insulin-like growth factor i
EP0600372B1 (de) 1992-12-02 1997-02-05 Hoechst Aktiengesellschaft Verfahren zur Gewinnung von Proinsulin mit korrekt verbundenen Cystinbrücken
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
FR2729972B1 (fr) * 1995-01-31 1997-04-18 Sanofi Sa Procede d'extraction de proteines periplasmiques de microorganismes procaryotes en presence d'arginine
US5714371A (en) * 1995-05-12 1998-02-03 Schering Corporation Method for refolding insoluble aggregates of hepatitis C virus protease
US5728804A (en) * 1995-06-02 1998-03-17 Research Corporation Technologies, Inc. Use of cyclodextrins for protein renaturation
CA2257122C (en) * 1996-06-11 2004-04-06 Boehringer Mannheim Gmbh Method of activating denatured protein
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US6653098B1 (en) * 1998-02-23 2003-11-25 G. D. Searle & Co. Method of producing mouse and human endostatin
DE19850429A1 (de) * 1998-10-27 2000-05-04 Andre Schrattenholz Fragmente
EP1048732A1 (de) * 1999-04-26 2000-11-02 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen
EP1077263A1 (de) * 1999-07-29 2001-02-21 F.Hoffmann-La Roche Ag Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen durch Co-Sekretion von Chaperonen
DE60129432T2 (de) 2000-05-16 2008-04-17 Bolder Biotechnology, Inc., Louisville Verfahren zur rückfaltung von proteinen mit freien cysteinresten
DE10105912A1 (de) * 2001-02-09 2002-08-14 Roche Diagnostics Gmbh Rekombinante Proteinase K
DE10105911A1 (de) 2001-02-09 2002-08-14 Roche Diagnostics Gmbh Expression der rekombinanten Proteinase K aus Tritirachium album in Hefe
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
WO2008008975A2 (en) 2006-07-14 2008-01-17 Genentech, Inc. Refolding of recombinant proteins
EP2102355B1 (en) 2006-12-14 2016-03-02 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
AU2011229491B2 (en) 2010-03-17 2015-02-05 Ratiopharm Gmbh Method for obtaining biologically active recombinant human G-CSF
WO2012054679A1 (en) * 2010-10-20 2012-04-26 Medimmune, Llc Methods for processing inclusion bodies
HUP1200171A1 (hu) 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására
HUP1200172A2 (en) 2012-03-19 2013-10-28 Richter Gedeon Nyrt Methods for refolding g-csf from inclusion bodies
CN103852527B (zh) * 2012-12-05 2015-05-13 中国科学院大连化学物理研究所 一种高通量蛋白质样品预处理装置
US10457716B2 (en) 2014-08-06 2019-10-29 University Of Notre Dame Du Lac Protein folding and methods of using same
NZ746109A (en) 2016-12-30 2022-12-23 Biogend Therapeutics Co Ltd Recombinant polypeptides and nucleic acid molecules, compositions, and methods of making and uses thereof
WO2022129460A1 (en) 2020-12-18 2022-06-23 Richter Gedeon Nyrt. Methods for the purification of refolded fc-peptide fusion protein

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5135481A (ja) * 1974-09-18 1976-03-25 Fujiwa Kako Kk Kojundohitorokinaaze no seiho
US4468633A (en) 1982-04-28 1984-08-28 The Bendix Corporation Adjustable microwave power combiner for a plurality of coaxially mounted impatt diodes
AR241654A1 (es) 1982-05-05 1992-10-30 Genentech Inc Procedimiento para producir activador de plasminogeno de tejido humano.
US4432895A (en) * 1982-11-24 1984-02-21 Hoffmann-La Roche Inc. Monomeric interferons
GR79124B (da) * 1982-12-22 1984-10-02 Genentech Inc
WO1984003711A1 (en) * 1983-03-25 1984-09-27 Celltech Ltd A process for the production of a protein
JPS6051119A (ja) * 1983-08-30 1985-03-22 Green Cross Corp:The ウロキナ−ゼ乾燥製剤
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
FR2596360B1 (fr) * 1986-04-01 1989-02-17 Sotralentz Sa Conteneur sur palette avec dispositif de protection en treillis plie et renforce
JPH0651119A (ja) * 1992-07-28 1994-02-25 Sekisui Chem Co Ltd 位相差板の製造方法

Also Published As

Publication number Publication date
HUT43643A (en) 1987-11-30
HK153596A (en) 1996-08-16
DD260517A5 (de) 1988-09-28
EP0219874A2 (de) 1987-04-29
ES2061434T3 (es) 1994-12-16
UA6023A1 (uk) 1994-12-29
EP0253823A1 (de) 1988-01-27
WO1987002673A2 (en) 1987-05-07
ZA868012B (en) 1987-06-24
ATE98648T1 (de) 1994-01-15
CA1329157C (en) 1994-05-03
FI933868A0 (fi) 1993-09-03
IE62634B1 (en) 1995-02-22
AU4132189A (en) 1990-01-04
IL80325A (en) 1992-06-21
IL80325A0 (en) 1987-01-30
FI94050B (fi) 1995-03-31
FI95578B (fi) 1995-11-15
FI95578C (fi) 1996-02-26
DK320387D0 (da) 1987-06-23
ES2020498A4 (es) 1991-08-16
YU179686A (en) 1988-06-30
FI872753A0 (fi) 1987-06-22
FI872753A (fi) 1987-06-22
CZ752686A3 (en) 1996-01-17
DE3537708C2 (da) 1993-07-08
PT83609A (de) 1986-11-01
ES2020498T3 (es) 1996-04-01
DK175091B1 (da) 2004-05-24
JPS62502895A (ja) 1987-11-19
AU590029B2 (en) 1989-10-26
HRP921075A2 (en) 1995-06-30
HK153496A (en) 1996-08-16
KR900009139B1 (ko) 1990-12-22
DK175109B1 (da) 2004-06-07
YU47185B (sh) 1995-01-31
SU1607689A3 (ru) 1990-11-15
DE3650449D1 (de) 1996-01-25
EP0219874A3 (en) 1988-02-10
GR920300062T1 (en) 1992-08-31
AU6599386A (en) 1987-05-19
DE3537708A1 (de) 1987-04-23
JPH04218387A (ja) 1992-08-07
PT83609B (pt) 1988-10-14
IE862683L (en) 1987-04-23
SK278317B6 (en) 1996-10-02
GR3018410T3 (en) 1996-03-31
WO1987002673A3 (fr) 1987-10-22
EP0393725A1 (de) 1990-10-24
JPH0824594B2 (ja) 1996-03-13
EP0393725B1 (de) 1995-12-13
ATE131489T1 (de) 1995-12-15
HRP921075B1 (en) 1999-02-28
SK752686A3 (en) 1996-10-01
FI933868A (fi) 1993-09-03
EP0219874B1 (de) 1993-12-15
AU607083B2 (en) 1991-02-21
DE3689404D1 (de) 1994-01-27
KR870700601A (ko) 1987-12-30
SI8611796B (sl) 1998-06-30
FI94050C (fi) 1995-07-10
JPH0728745B2 (ja) 1995-04-05
DK320387A (da) 1987-06-23
HU204855B (en) 1992-02-28
CZ280727B6 (cs) 1996-04-17
SI8611796A (sl) 1996-10-31

Similar Documents

Publication Publication Date Title
DK200001897A (da) Fremgangsmåde til aktivering af genteknologisk fremstillede, heterologe, disulfidbroer indeholdende eukaryotiske proteiner
KR900006515A (ko) 유전자 공학적으로 생성되고 원핵생물내 발현된 항체의 활성화 방법
DE69934585D1 (de) Rückfaltung von protein-aggregaten und einschlussteilchen durch hohen druck
CA2090701C (en) Solubilization of proteins in active forms
AU2002340510A1 (en) Process for renaturation of recombinant, disulfide containing proteins at high protein concentrations in the presence of amines
EP0804461A1 (en) Process for folding of proteins like recombinant hirudin or epidermal growth factor

Legal Events

Date Code Title Description
PUP Patent expired